The MarketWatch News Department was not involved in the creation of this content.-- Heart disease affects approximately 10 percent of dogs in their lifetime1 -- VETMEDIN(R) (pimob ...
The approval broadens Vetmedin’s label, which already covers management of mild to severe congestive heart failure in dogs with clinical myxomatous mitral valve disease or dilated cardiomyopathy.
Canine mitral valve disease, most commonly stemming from myxomatous degeneration, is the predominant acquired cardiac condition in dogs. This disease is characterised by progressive deterioration of ...
Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had ...